The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > COLUMN
COLUMN
- Doubling Down on Digital
May 26, 2017
- Global Opportunities for Global Minds
April 21, 2017
- Will Tepid Pricing Debate Only Go Full-Throttle after Golden Week Holidays?
March 30, 2017
- Some Japanese Pharmaceutical Workers May Slowly Be Working Themselves to Death
March 17, 2017
- The Best Recruiters Are Just a Little Paranoid
February 17, 2017
- 5 Killer Questions for HR to Ask Recruiters
January 20, 2017
- What Pharma Can Learn from the Airline Industry
December 16, 2016
- Near Death at Singapore General Hospital and 5 Lessons I Learnt
October 20, 2016
- Reasons for a “Hold”
August 9, 2016
- It’s Time for Market Access to Play a Leading Role
April 22, 2016
- Biosimilars Are the New Black
March 25, 2016
- Technology Provides Opportunities for Medical Device Companies
February 18, 2016
- Don’t Accept the Offer
January 22, 2016
- It’s Your Choice
December 18, 2015
- Ask a Question and Shut Up
November 27, 2015
- Recruiternomics
October 30, 2015
- Pharma Companies in JPAC Are Searching for the Goldilocks Candidate
September 25, 2015
- No… Your Company Is Not like a Family!
August 28, 2015
- What’s Your Pharma Company’s Brand in Japan?
July 24, 2015
- Current Topics of New Drug Development and Marketing in the World: 2
July 10, 2015
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…